219 related articles for article (PubMed ID: 27460639)
21. CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges.
Demirci S; Leonard A; Haro-Mora JJ; Uchida N; Tisdale JF
Adv Exp Med Biol; 2019; 1144():37-52. PubMed ID: 30715679
[TBL] [Abstract][Full Text] [Related]
22. Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR/Cas9 technology.
Estève J; Blouin JM; Lalanne M; Azzi-Martin L; Dubus P; Bidet A; Harambat J; Llanas B; Moranvillier I; Bedel A; Moreau-Gaudry F; Richard E
Biochem Biophys Res Commun; 2019 Oct; 517(4):677-683. PubMed ID: 31402115
[TBL] [Abstract][Full Text] [Related]
23. Concurrent progress of reprogramming and gene correction to overcome therapeutic limitation of mutant ALK2-iPSC.
Kim BY; Jeong S; Lee SY; Lee SM; Gweon EJ; Ahn H; Kim J; Chung SK
Exp Mol Med; 2016 Jun; 48(6):e237. PubMed ID: 27256111
[TBL] [Abstract][Full Text] [Related]
24. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells.
DeWitt MA; Magis W; Bray NL; Wang T; Berman JR; Urbinati F; Heo SJ; Mitros T; Muñoz DP; Boffelli D; Kohn DB; Walters MC; Carroll D; Martin DI; Corn JE
Sci Transl Med; 2016 Oct; 8(360):360ra134. PubMed ID: 27733558
[TBL] [Abstract][Full Text] [Related]
25. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
[TBL] [Abstract][Full Text] [Related]
26. Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones.
Suzuki K; Yu C; Qu J; Li M; Yao X; Yuan T; Goebl A; Tang S; Ren R; Aizawa E; Zhang F; Xu X; Soligalla RD; Chen F; Kim J; Kim NY; Liao HK; Benner C; Esteban CR; Jin Y; Liu GH; Li Y; Izpisua Belmonte JC
Cell Stem Cell; 2014 Jul; 15(1):31-6. PubMed ID: 24996168
[TBL] [Abstract][Full Text] [Related]
27. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
[TBL] [Abstract][Full Text] [Related]
28. Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration.
Burnight ER; Gupta M; Wiley LA; Anfinson KR; Tran A; Triboulet R; Hoffmann JM; Klaahsen DL; Andorf JL; Jiao C; Sohn EH; Adur MK; Ross JW; Mullins RF; Daley GQ; Schlaeger TM; Stone EM; Tucker BA
Mol Ther; 2017 Sep; 25(9):1999-2013. PubMed ID: 28619647
[TBL] [Abstract][Full Text] [Related]
29. Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice.
Wilkinson AC; Dever DP; Baik R; Camarena J; Hsu I; Charlesworth CT; Morita C; Nakauchi H; Porteus MH
Nat Commun; 2021 Jan; 12(1):686. PubMed ID: 33514718
[TBL] [Abstract][Full Text] [Related]
30. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9.
Paquet D; Kwart D; Chen A; Sproul A; Jacob S; Teo S; Olsen KM; Gregg A; Noggle S; Tessier-Lavigne M
Nature; 2016 May; 533(7601):125-9. PubMed ID: 27120160
[TBL] [Abstract][Full Text] [Related]
31. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells.
Dever DP; Bak RO; Reinisch A; Camarena J; Washington G; Nicolas CE; Pavel-Dinu M; Saxena N; Wilkens AB; Mantri S; Uchida N; Hendel A; Narla A; Majeti R; Weinberg KI; Porteus MH
Nature; 2016 Nov; 539(7629):384-389. PubMed ID: 27820943
[TBL] [Abstract][Full Text] [Related]
32. CRISPR/Cas9-based gene-editing technology for sickle cell disease.
Ma L; Yang S; Peng Q; Zhang J; Zhang J
Gene; 2023 Jul; 874():147480. PubMed ID: 37182559
[TBL] [Abstract][Full Text] [Related]
33. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
Wen J; Tao W; Hao S; Zu Y
J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
[TBL] [Abstract][Full Text] [Related]
34. Robust in vivo transduction of a genetically stable Epstein-Barr virus episome to hepatocytes in mice by a hybrid viral vector.
Gallaher SD; Gil JS; Dorigo O; Berk AJ
J Virol; 2009 Apr; 83(7):3249-57. PubMed ID: 19158239
[TBL] [Abstract][Full Text] [Related]
35. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs.
Xu P; Tong Y; Liu XZ; Wang TT; Cheng L; Wang BY; Lv X; Huang Y; Liu DP
Sci Rep; 2015 Jul; 5():12065. PubMed ID: 26156589
[TBL] [Abstract][Full Text] [Related]
36. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
[TBL] [Abstract][Full Text] [Related]
37. Preclinical evaluation for engraftment of CD34
Uchida N; Li L; Nassehi T; Drysdale CM; Yapundich M; Gamer J; Haro-Mora JJ; Demirci S; Leonard A; Bonifacino AC; Krouse AE; Linde NS; Allen C; Peshwa MV; De Ravin SS; Donahue RE; Malech HL; Tisdale JF
Cell Rep Med; 2021 Apr; 2(4):100247. PubMed ID: 33948577
[TBL] [Abstract][Full Text] [Related]
38. Generation and characterization of induced pluripotent stem cell line (IGIBi001-A) from a sickle cell anemia patient with homozygous β-globin mutation.
Bhargava N; Jaitly S; Goswami SG; Jain S; Chakraborty D; Ramalingam S
Stem Cell Res; 2019 Aug; 39():101484. PubMed ID: 31255831
[TBL] [Abstract][Full Text] [Related]
39. Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9.
Ben Jehuda R; Shemer Y; Binah O
Stem Cell Rev Rep; 2018 Jun; 14(3):323-336. PubMed ID: 29623532
[TBL] [Abstract][Full Text] [Related]
40. Rapid Generation of Human Genetic Loss-of-Function iPSC Lines by Simultaneous Reprogramming and Gene Editing.
Tidball AM; Dang LT; Glenn TW; Kilbane EG; Klarr DJ; Margolis JL; Uhler MD; Parent JM
Stem Cell Reports; 2017 Sep; 9(3):725-731. PubMed ID: 28781079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
